Results 131 to 140 of about 1,630,140 (194)
Category IV indications for therapeutic apheresis: ASFA fourth special issue
The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned
Shaz, Beth H. +10 more
core +1 more source
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs +15 more
wiley +1 more source
[The Italian Registry for Therapeutic Apheresis: fifteen years of activity]
There is currently no consensus about the indications for therapeutic apheresis, also due to the lack of large clinical trials. A registry where all the data can be organized and analyzed therefore becomes a priority for all professionals involved in ...
Aureli, Fabio, Ferraro, Pietro Manuel
core +1 more source
ABO-incompatible renal transplants often require expensive pre-transplant conditioning using therapeutic apheresis (TA) procedures to reduce the titers of isoagglutinins in the recipients, which may have adverse effects on the graft acceptance and ...
Prashant Pandey +6 more
doaj +1 more source
Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax
Venetoclax‐induced Bcl‐2 inhibition corresponds with Mcl‐1 attenuation and decrease of Nucleolin (NCL) level and activity in sensitive cells. Simultaneously, distinct cell subpopulations with opposite mitochondrial (CellROX label, magenta) and cellular (H2DCFDA stain, green) ROS occur, and the H2DCFDA‐positive population shows markers of early ...
Kateřina Wolfová +2 more
wiley +1 more source
Should the Therapeutic Apheresis Method Be Added to Treatment in the COVID-19 Outbreak? [PDF]
Şahin M, Yıldız A.
europepmc +1 more source
Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis. [PDF]
Stegmayr B +39 more
europepmc +1 more source
A loxoscelism case received therapeutic apheresis and hyperbaric oxygen therapy. [PDF]
Cetinkaya A +3 more
europepmc +1 more source
Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy. [PDF]
Colpo A +4 more
europepmc +1 more source

